Compound as kif18a inhibitor
AssigneeHangzhou Innogate Pharma Co., Ltd.
InventorsHancheng ZHANG, Congcong CAI, Wei JIA
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound as a KIF18A inhibitor. Specifically, the present invention provides a compound having a structure as represented by the following formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate and solvate thereof. The compound can be used for treating or preventing diseases or symptoms associated with the activity or expression amount of KIF18A.
Claims15
A compound of the following formula (I), or the optical isomers, pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates thereof:
- wherein in the formula (I):
- A is selected from —Y—R1;
- wherein, Y is selected from the bond, —S(O)—, —S(O)2—, —S(O)(NH)—, —S(O)2NRa—, —NRaS(O)2—, —NRaS(O)2NRa—, —P(O)(Rq)—, —P(O)(Rq)NRa—, —NRaP(O)(Rq)—, —P(O)(Rq)O—, —OP(O)(Rq)—, —NRa—, —O—, —S—, —C(O)NRa—, —NRaC(O)—, —C(O)O—, —OC(O)—, —NRaC(O)NRa—, —OC(O)NRa—, —NRaC(O)O—, C2-4 alkenyl, and C2-4 alkynyl;
- wherein each Ra is independently selected from hydrogen and C1-4 alkyl;
- each Rq is independently selected from C1-4 alkyl, C3-6 cycloalkyl, and 3- to 6-membered heterocyclyl;
- or Rq and R1 together with the attached phosphorus atom form optionally substituted 4- to 8-membered ring structure, while the ring structure may additionally contain 0-1 heteroatoms optionally selected from N, O and S;
- or A is Formula (Ia):
- wherein, “” refers to the site of formula (Ia) which attaches to the remaining fragment of the compound of formula (I);
- L is selected from —C(O)NRb—, —NRbC(O)—, —NRbC(O)NRb—, —OC(O)NRb—, —C(O)O—, —OC(O)—, —NRbC(O)O—, —S(O)2NRb—, —NRbS(O)2—, —NRb—, —O—, 3- to 6-membered heterocyclyl, and heteroaryl;
- wherein each Rb is independently hydrogen or C1-4 alkyl;
- B is Formula (Ib) or (Id):
- wherein “” refers to the site of formula (Ib) or (Id) which attach to the L in a compound of formula (I);
- X1, X2, X3 and X4 are each independently selected from N or CRc;
- wherein Rc is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkynyl, C1-4 alkoxy, hydroxy, C1-4 haloalkoxy, CN, NRdRd, C3-6 cycloalkyl, and 3- to 8-heterocyclic group;
- wherein each Rd is independently selected from the group consisting of hydrogen, C1-4 alkyl, and C1-4 haloalkyl;
- U is selected from N or CRe;
- wherein Re is selected from the group consisting of hydrogen, halogen, and C1-4 alkyl;
- Z1, Z2 and Z3 are each independently selected from N and CRm;
- wherein Rm is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, hydroxy, C1-4 haloalkoxy, CN, NRdRd, C3-8 cycloalkyl, and 3- to 8-membered heterocyclyl;
- wherein, each Rd are as defined above;
- D is selected from the group consisting of bond, —O—, —S—, NRd—, C1-4 alkyl, and C2-4 alkynyl;
- G is 3-10 membered saturated or unsaturated cyclic structure, which optionally containing 0, 1 or 2 heteroatoms selected from N, O and S, or optionally substituted by R6 or R7;
- R1 is selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 10-membered heterocyclyl;
- said alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl being optionally substituted with one or more groups selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 haloalkenyl, C2-4 alkynyl, C2-4 haloalkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, ORf, SRf, NRdRd, —OC1-4 alkyl-ORf, —OC1-4 alkyl-NRdRd, —NRdC1-4 alkyl-ORf, —NRdC1-4 alkyl-NRdRd, —C(O)Rg, —C(O)ORf, —OC(O)R9, —C(O)NRdRd, —NRdC(O)Rg, —NRdC(O)NRdRd, —OC(O)NRdRd, —NRdC(O)ORf, —OC(O)ORf, —S(O)2NRdRd, —NRdS(O)2R9, and —NRdS(O)2NRdRd;
- or said cycloalkyl or heterocyclyl is optionally substituted with =M;
- wherein, Rf is selected from hydrogen, C1-4 alkyl, and C1-4 haloalkyl;
- Rg is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl, aryl, and heteroaryl;
- M is selected from 0 and CRhRi;
- wherein, Rh and R1 are each independently selected from hydrogen, halogen, and C1-4 alkyl;
- wherein the alkyl in Rh or Ri is optionally substituted with one or more groups selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, hydroxy, NRdRd, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl;
- or Rh and Ri, together with the carbon atom to which they are attached, form a 3- to -6-membered ring structure optionally containing 0, 1 or 2 heteroatoms selected from N, O and S;
- each Rd is as defined above;
- R2 and R3 are each independently selected from the group consisting of hydrogen, fluorine, and C1-4 alkyl;
- wherein the alkyl is optionally substituted with one or more groups selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, hydroxyl, NRdRd, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl;
- wherein, each Rd is defined as above;
- each R4 is independently selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkoxy-C1-4 alkyl, hydroxy, hydroxyl-C1-4 alkyl, C1-4 haloalkoxy, C10.4 haloalkoxy-C1-4 alkyl, and CN;
- R6 is selected from -Q-R8;
- wherein Q is selected from bond, —S(O)—, —S(O)2—, —S(O)(NH)—, —S(O)2NRa—, —NRaS(O)2—, —NRaS(O)2NRa—, —NRa—, —O—, —S—, —C(O)NRa—, —NRaC(O)—, —C(O)O—, —OC(O)—, —NRaC(O)NRa—, —OC(O)NRa—, —NRaC(O)O—, C2-4 alkenyl, and C2-4 alkynyl;
- where each Ra is as defined above;
- R6 and R7 are each independently selected from hydrogen, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl;
- or R6 and R7 together with the carbon atom to which they are attached form a 3- to 6-membered ring structure, optionally containing 0, 1, or 2 heteroatoms selected from N, O and S;
- or R6 and R7 together with the carbon atom to which they are attached form C=T, wherein T is selected from CRjRk;
- wherein R3 and Rk are each independently selected from the group consisting of hydrogen, deuterium, halogen, and C1-4 alkyl;
- said alkyl is optionally substituted with one or more group selected from halogen, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, ORf, SRf, and NRdRd;
- or Ri and Rk together with the carbon atom to which they are attached form a 3- to -6 membered ring structure which optionally contains 0 or 1 heteroatom selected from N, O and S;
- Rd and Rf are as defined above;
- R8 is selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 10-membered heterocyclyl;
- said alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl being optionally substituted with one or more groups selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, ORf, SRf, NRdRd, —OC1-4 alkyl-ORf, —OC1-4 alkyl-NRdRd, —NRdC1-4 alkyl-ORf, —NRdC1-4 alkyl-NRdRd, —C(O)Rg, —C(O)ORf, —OC(O)R9, —C(O)NRdRd, —NRdC(O)Rg, —NRdC(O)NRdRd, —OC(O)NRdRd, —NRdC(O)ORf, —OC(O)ORf, —S(O)2NRdRd, —NRdS(O)2Rg, and —NRdS(O)2NRdRd;
- or said cycloalkyl or heterocyclyl is substituted by =M;
- wherein, Rf is selected from hydrogen, C1-4 alkyl, and C1-4 haloalkyl;
- Rg is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl, aryl, and heteroaryl;
- M is selected from O and CRhRi;
- wherein, Rh and Ri are each independently selected from hydrogen, halogen, and C1-4 alkyl;
- wherein the alkyl in Rh or Ri is optionally substituted with one or more groups selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, hydroxy, NRdRd, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl;
- or Rh and Ri together with the carbon atoms to which they are attached form a 3- to -6-membered ring structure optionally containing 0, 1, or 2 heteroatoms selected from N, O and S;
- each Rd is as defined above;
- p and q are each independently selected from 0, 1, 2, 3, 4, 5 and 6;
- with the proviso that p and q are not simultaneously 0;
- m is selected from 0, 1, 2, 3 and 4;
- k and n are selected from 1, 2, 3, 4 and 5;
- wherein, each of the above mentioned alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally and each independently substituted by 1-3 substituents selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, NO2, ORf, SRf, NRdRd, C(O)R9, C(O)ORf, C(O)NRdRd, NRdC(O)Rg, NRdS(O)2R9, and S(O)2R9, provided that the chemical structure formed is stable and meaningful;
- wherein Rd, Rf, and Rg are as defined above;
- unless otherwise specified, the aryl is aromatic groups having 6 to 12 carbon atoms;
- the heteroaryl is 5- to 15-membered (preferably 5- to 12-membered) heteroaromatic groups;
- and the cyclic structure is saturated or unsaturated cyclic groups with or without heteroatoms.
Dependencies are inferred from the claim text.